{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:19:31Z","timestamp":1790623171889,"version":"4.1.0"},"reference-count":36,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age. Women with PCOS often have metabolic disorders such as insulin resistance (IR), type 2 diabetes (T2DM), obesity, and metabolic syndrome (MetS). The assessment of visceral adiposity and dysfunctional adipose tissue is crucial for understanding the metabolic risks associated with PCOS. The visceral adiposity index (VAI) and the dysfunctional adiposity index (DAI) are two novel metabolic indices that more specifically assess adipose tissue dysfunction and visceral fat accumulation. This study aimed to evaluate the clinical utility of VAI and DAI as predictive markers for metabolic complications such as insulin resistance (IR) and metabolic syndrome (MetS) in women with PCOS. Materials and Methods: This cross-sectional study included 92 women diagnosed with PCOS based on the 2023 revised Rotterdam criteria, as well as 68 healthy controls. Anthropometric and biochemical parameters, including fasting glucose, insulin, lipid profile, and hormonal markers, were recorded. VAI and DAI were calculated using established formulas derived from previous validated studies. Results: The mean VAI in PCOS patients was 4.26 \u00b1 3.23, compared to 2.61 \u00b1 1.92 in controls (p = 0.003). The mean DAI in PCOS patients was 3.00 \u00b1 1.86, while in controls it was 1.86 \u00b1 1.22 (p = 0.003). Both VAI (Area Under the Curve [AUC] = 0.639) and DAI (AUC = 0.635) did not demonstrate statistically significant diagnostic performance for PCOS itself, but they were strongly associated with metabolic disturbances within the PCOS group. VAI and DAI values were significantly elevated in PCOS patients with IR (p &lt; 0.001) and MetS (p &lt; 0.001). For MetS in PCOS patients, VAI demonstrated the highest predictive ability, with an AUC of 0.87 and a cutoff of 4.73 (sensitivity 62%, specificity 92%), while DAI had an AUC of 0.86 with a cutoff of 2.44 (sensitivity 74%, specificity 80%). Regarding IR in PCOS patients, VAI had an AUC of 0.75 with a cutoff of 2.56 (sensitivity 82%, specificity 56%), while DAI had an AUC of 0.74 with a cutoff of 1.59, showing a sensitivity of 82% and a specificity of 55%. Conclusions: Although VAI and DAI are not suitable for diagnosing PCOS, they provide valuable insights into the metabolic risks associated with the condition. VAI and DAI can serve as promising biomarkers for identifying IR and MetS risk in women with PCOS. Their integration into clinical practice may facilitate the early detection of cardiometabolic complications, offering a more specific metabolic risk assessment compared to traditional anthropometric measures.<\/jats:p>","DOI":"10.3390\/medicina61030424","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:45:42Z","timestamp":1740725142000},"page":"424","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Visceral and Dysfunctional Adiposity Indices as Predictors of Insulin Resistance and Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7472-551X","authenticated-orcid":false,"given":"Bet\u00fcl","family":"Keyif","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, D\u00fczce University, 81620 D\u00fczce, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Yavuzcan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, Sa\u011fl\u0131k Bilimleri University, Ankara Bilkent City Hospital, 06800 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Che, Y., Yu, J., Li, Y.S., Zhu, Y.C., and Tao, T. (2023). Polycystic Ovary Syndrome: Challenges and Possible Solutions. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041500"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Wu, Z., Liang, G., Zhang, Y., and Li, R. (Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol., 2025). Risk factors for metabolic dysfunction-associated steatotic liver disease in patients with polycystic ovary syndrome in East Asia: A review and meta-analysis, Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol., in press.","DOI":"10.1016\/j.eprac.2025.01.011"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hofmann, K., Decrinis, C., Bitterlich, N., Tropschuh, K., Stute, P., and Bachmann, A. (2025). Body image and mental health in women with polycystic ovary syndrome-a cross-sectional study. Arch. Gynecol. Obstet.","DOI":"10.1007\/s00404-024-07913-4"},{"key":"ref_4","first-page":"e25076","article-title":"Cardio-Metabolic Disease and Polycystic Ovarian Syndrome (PCOS): A Narrative Review","volume":"14","author":"Sangaraju","year":"2022","journal-title":"Cureus"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Moreira, V.C., and de Souza Silva, C.M. (2022). Altered Visceral Adipose Tissue Predictors and Women\u2019s Health: A Unicenter Study. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19095505"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/clinem\/dgad356","article-title":"Adipose Tissue Dysfunction in Polycystic Ovary Syndrome","volume":"109","author":"Bril","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_7","first-page":"141","article-title":"Is the polycystic ovary syndrome the causative of the increase in inflammatory markers and metabolic risk?","volume":"29","author":"Galluzzo","year":"2013","journal-title":"Gynecol. Endocrinol. Off. J. Int. Soc. Gynecol. Endocrinol."},{"key":"ref_8","first-page":"101965","article-title":"Visceral adiposity index (VAI) and dysfunctional adiposity index (DAI). Relationship with obesity parameters","volume":"49","year":"2023","journal-title":"Semergen"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2147\/DMSO.S397043","article-title":"Visceral Adiposity Index and Lipid Accumulation Product as Effective Markers of Different Obesity Phenotypes in Korean Adults: A Cross-Sectional Analysis","volume":"16","author":"Yu","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sadeghi, H.M., and Adeli, I. (2022). Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020583"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/jdi.13685","article-title":"Association between visceral adiposity index and risk of prediabetes: A meta-analysis of observational studies","volume":"13","author":"Wang","year":"2022","journal-title":"J. Diabetes Investig."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Christ, J.P., and Cedars, M.I. (2023). Current Guidelines for Diagnosing PCOS. Diagnostics, 13.","DOI":"10.3390\/diagnostics13061113"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Jungert, A., and Frank, J. (2021). Intra-Individual Variation and Reliability of Biomarkers of the Antioxidant Defense System by Considering Dietary and Lifestyle Factors in Premenopausal Women. Antioxidants, 10.","DOI":"10.3390\/antiox10030448"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clinre.2019.04.002","article-title":"The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: A population-based longitudinal study","volume":"44","author":"Okamura","year":"2020","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/21623945.2021.1893452","article-title":"Dysfunctional adiposity index as a marker of adipose tissue morpho-functional abnormalities and metabolic disorders in apparently healthy subjects","volume":"10","year":"2021","journal-title":"Adipocyte"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hor\u00e1kov\u00e1, D., \u0160t\u011bp\u00e1nek, L., Janout, V., Janoutov\u00e1, J., Pastucha, D., Koll\u00e1rov\u00e1, H., Petr\u00e1kov\u00e1, A., \u0160t\u011bp\u00e1nek, L., Hus\u00e1r, R., and Martin\u00edk, K. (2019). Optimal Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Cut-Offs: A Cross-Sectional Study in the Czech Population. Medicina, 55.","DOI":"10.3390\/medicina55050158"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kassi, E., Pervanidou, P., Kaltsas, G., and Chrousos, G. (2011). Metabolic syndrome: Definitions and controversies. BMC Med., 9.","DOI":"10.1186\/1741-7015-9-48"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2405097","DOI":"10.1080\/09513590.2024.2405097","article-title":"Impact of body mass index and polycystic ovary syndrome (PCOS) subtypes on periodontal health in Chinese women with PCOS and periodontitis","volume":"40","author":"Liu","year":"2024","journal-title":"Gynecol. Endocrinol. Off. J. Int. Soc. Gynecol. Endocrinol."},{"key":"ref_19","first-page":"7182","article-title":"The novel predictor of metabolic risk in patients with polycystic ovary syndrome: Could it be the visceral adiposity index?","volume":"26","author":"Apaydin","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40618-016-0582-x","article-title":"Visceral adiposity index levels in overweight and\/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters","volume":"40","author":"Durmus","year":"2017","journal-title":"J. Endocrinol. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Uysal, E., Tammo, O., Soylemez, E., Inceb\u0131y\u0131k, M., Filiz, D., and Alci, M. (2024). Significance of measuring anthropometric and atherogenic indices in patients with polycystic ovary syndrome. BMC Endocr. Disord., 24.","DOI":"10.1186\/s12902-024-01701-6"},{"key":"ref_22","first-page":"129","article-title":"Body Image, Self-Esteem and Depressive Symptomatology in Women with Polycystic Ovary Syndrome","volume":"51","author":"Akbaba","year":"2014","journal-title":"Noro Psikiyatr. Ars."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pourkhani, Z., and Jahanian Sadatmahalleh, S. (2025). The association between the follicular distribution pattern of polycystic ovaries and metabolic syndrome development in patients with polycystic ovary syndrome a prospective cohort study. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-89745-z"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s43032-022-00864-8","article-title":"The Association Between Polycystic Ovary Syndrome and Metabolic Syndrome in Adolescents: A Systematic Review and Meta-analysis","volume":"30","author":"Fu","year":"2023","journal-title":"Reprod. Sci."},{"key":"ref_25","first-page":"e60975","article-title":"Exploring Serum Vitamin D, Sex Hormones, and Lipid Profile Disparities in Women with and Without Polycystic Ovarian Syndrome: A Case-Control Study","volume":"16","author":"Akinola","year":"2024","journal-title":"Cureus"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Liu, D., Gao, X., Pan, X.F., Zhou, T., Zhu, C., Li, F., Fan, J.G., Targher, G., and Zhao, J. (2023). The hepato-ovarian axis: Genetic evidence for a causal association between non-alcoholic fatty liver disease and polycystic ovary syndrome. BMC Med., 21.","DOI":"10.1186\/s12916-023-02775-0"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Mouchti, S., Orliacq, J., Reeves, G., and Chen, Z. (2023). Assessment of correlation between conventional anthropometric and imaging-derived measures of body fat composition: A systematic literature review and meta-analysis of observational studies. BMC Med. Imaging, 23.","DOI":"10.1186\/s12880-023-01063-w"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Szyd\u0142owska, I., Nawrocka-Rutkowska, J., Gorzko, A., Paw\u0142owski, H., Starczewski, A., and Szczuko, M. (2025). Changes in Hormonal Profile and Body Mass Index in Women with Polycystic Ovary Syndrome After Probiotic Intake: A 12-Week Placebo-Controlled and Randomized Clinical Study. Nutrients, 17.","DOI":"10.3390\/nu17030405"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Fry, J.M., and Temple, J.B. (2022). Discrepancies in self-reported and measured anthropometric measurements and indices among older Australians: Prevalence and correlates. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-14326-y"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jpeds.2022.09.009","article-title":"Anthropometric Equations to Predict Visceral Adipose Tissue in European and American Youth","volume":"253","author":"Samouda","year":"2023","journal-title":"J. Pediatr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/oby.20096","article-title":"The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome","volume":"21","author":"Oh","year":"2013","journal-title":"Obesity"},{"key":"ref_32","first-page":"e12353","article-title":"Optimal Cutoff Points for Anthropometric Variables to Predict Insulin Resistance in Polycystic Ovary Syndrome","volume":"15","author":"Hatami","year":"2017","journal-title":"Int. J. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijcard.2016.10.040","article-title":"Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes","volume":"225","author":"Mantovani","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_34","first-page":"2002","article-title":"The dysfunctional adiposity index is a clinical surrogate of pericardial fat in adults without premature CVD: A sub-analysis of the GEA Mexican study control group. Nutrition, metabolism, and cardiovascular diseases","volume":"34","year":"2024","journal-title":"NMCD"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Gonz\u00e1lez, A.A., Jover, A.M., Mart\u00ednez, C.S., Artal, P.M., Bote, S.A., Jan\u00e9, B.A., and Ram\u00edrez-Manent, J.I. (2022). The CUN-BAE, Deurenberg Fat Mass, and visceral adiposity index as confident anthropometric indices for early detection of metabolic syndrome components in adults. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-19343-w"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Jalali, M., Bahadoran, Z., Mirmiran, P., Azizi, F., and Hosseinpanah, F. (2024). Severity of adipose tissue dysfunction is associated with progression of pre-diabetes to type 2 diabetes: The Tehran Lipid and Glucose Study. BMC Public Health, 24.","DOI":"10.1186\/s12889-023-17381-1"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/3\/424\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:44:05Z","timestamp":1760028245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/3\/424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["medicina61030424"],"URL":"https:\/\/doi.org\/10.3390\/medicina61030424","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}